Jee H. Kong

Wondu, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Risk of selected immune-mediated inflammatory diseases after solid organ transplantation in a Korean nationwide cohort.

Risk of selected immune-mediated inflammatory diseases after solid organ transplantation in a Korean nationwide cohort.

Journal: JAAD international

Published: July 11, 2026

Clinico-Pathologic Features of Adult Erdheim-Chester Disease in South Korea: A Multicenter Retrospective Study (KCSG LY22-15).

Clinico-Pathologic Features of Adult Erdheim-Chester Disease in South Korea: A Multicenter Retrospective Study (KCSG LY22-15).

Journal: Cancer research and treatment

Published: April 14, 2026

A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity.

A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity.

Journal: International journal of molecular sciences

Published: February 20, 2026

Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia.

Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia.

Journal: International journal of molecular sciences

Published: January 22, 2026

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal: Annals of hematology

Published: December 22, 2025

Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 24, 2025

Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor.

Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor.

Journal: Annals of hematology

Published: March 29, 2025

Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study.

Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study.

Journal: Therapeutic advances in hematology

Published: February 03, 2025

Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First-Line Chemotherapy.

Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First-Line Chemotherapy.

Journal: Thoracic cancer

Published: July 05, 2024

Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.

Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.

Journal: Leukemia research

Published: April 13, 2024

A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.

A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.

Journal: Blood research

Published: October 23, 2023

Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation.

Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation.

Journal: Frontiers in oncology

Published: May 29, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026